Keyphrases
Factor XI Deficiency
100%
Bleeding
34%
Polymorphism
32%
Thrombosis
31%
Risk Factors
29%
Thrombin Generation
29%
Recombinant Activated Factor VII (rFVIIa)
26%
Thrombophilia
22%
G1691A
19%
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
19%
Myelofibrosis
19%
Neonatal Alloimmune Thrombocytopenia
18%
Platelets
17%
Confidence Interval
17%
Recurrent Venous Thromboembolism
16%
Methylenetetrahydrofolate Reductase (MTHFR)
16%
Risk Assessment
16%
FXI Deficiency
16%
Odds Ratio
15%
Ovarian Vein Thrombosis
14%
Factor V Leiden
14%
Bleeding Risk
13%
Phacoemulsification
13%
Venous Thromboembolism
13%
Spleen
13%
Homozygote
13%
Non-associated
12%
Replacement Therapy
12%
Bleeding Disorders
12%
Ashkenazi Jews
12%
Heterozygote
11%
Bone Marrow
11%
Rare Bleeding Disorders
11%
Thrombophilias
11%
Homocysteine
10%
JAK2V617F
10%
Thrombotic
10%
Causal Factors
10%
Major Surgery
10%
Second Eye Involvement
10%
Donor Type
10%
Anticoagulant Treatment
10%
Microparticles
10%
Anticoagulants
10%
Antiphospholipid Antibodies
9%
Shear Wave Elastography
9%
Retinal Vein Occlusion
9%
Prothrombotic Factors
9%
Blood Flow
9%
Branch Retinal Vein Occlusion
9%
Medicine and Dentistry
Factor XI
75%
Bleeding
43%
Diseases
25%
Thrombosis
24%
Prevalence
24%
Platelet
23%
Phlebothrombosis
21%
Thrombophilia
17%
Factor V
17%
Thrombin
17%
Bleeding Disorder
15%
Prothrombin
15%
Cataract Surgery
15%
Polycythemia vera
14%
Myelofibrosis
14%
Ovarian Vein
14%
Phacoemulsification
14%
Factor V Leiden
13%
Allele
12%
Thrombocytopenia
12%
Recombinant Blood Clotting Factor 7a
12%
Factor VII
12%
Disease
12%
Cesarean Section
11%
Autoantibodies
11%
Antithrombotic
10%
Whole Body Radiation
10%
Substitution Therapy
10%
Major Surgery
10%
Venous Thromboembolism
10%
Deep Vein Thrombosis
10%
Gene Mutation
10%
Haemophilia A
10%
Odds Ratio
9%
Low Drug Dose
9%
Microparticle
9%
Shear Wave Elastography
9%
Arteritic Anterior Ischemic Optic Neuropathy
9%
Pregnancy Complication
9%
Blood Flow
9%
Jugular Vein Thrombosis
9%
Upper Extremity Deep Vein Thrombosis
9%
Antiphospholipid Antibody
9%
Systematic Review
9%
Meta-Analysis
9%
Allograft
9%
Neonatal Alloimmune Thrombocytopenia
9%
Thromboembolism
9%
Homozygote
9%
Cataract
8%
